Fibroblast growth factor 21 analogs for treating metabolic disorders

Frontiers in Endocrinology

Volumn 6, Issue NOV, 2015, Pages

  Zhang, Jun ^a   Li, Yang ^a  

^a AMGEN INC   (United States)

Author keywords

Antibody; Beta Klotho; Diabetes; FGF19; FGF21; FGFR1; Obesity; Therapy

Indexed keywords

ADIPONECTIN; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR 21; FIBROBLAST GROWTH FACTOR 4; MONOCLONAL ANTIBODY; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; UNCOUPLING PROTEIN 1;

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COLD EXPOSURE; DIABETES MELLITUS; DRUG TARGETING; ENERGY EXPENDITURE; GENE EXPRESSION; GLUCONEOGENESIS; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; LIPOLYSIS; LIVER DISEASE; METABOLIC DISORDER; NONHUMAN; OBESITY; REVIEW; THERMOGENESIS;

EID: 84949776698     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2015.00168     Document Type: Review

References (109)

1. Itoh N, Ornitz DM. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem (2011) 149:121-30. doi: 10.1093/jb/mvq121
2. Kelleher FC, O'Sullivan H, Smyth E, McDermott R, Viterbo A. Fibroblast growth factor receptors, developmental corruption and malignant disease. Carcinogenesis (2013) 34:2198-205. doi:10.1093/carcin/bgt254
3. Itoh N, Ornitz DM. Evolution of the Fgf and Fgfr gene families. Trends Genet (2004) 20:563-9. doi:10.1016/j.tig.2004.08.007
4. Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta (2000) 1492:203-6. doi:10.1016/S0167-4781(00)00067-1
5. Inagaki T, Dutchak P, Zhao G, Ding X, Gautron L, Parameswara V, et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab (2007) 5:415-25. doi:10.1016/j.cmet.2007.05.003
6. Ogawa Y, Kurosu H, Yamamoto M, Nandi A, Rosenblatt KP, Goetz R, et al. BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci U S A (2007) 104:7432-7. doi:10.1073/pnas.0701600104
7. Kharitonenkov A, Dunbar JD, Bina HA, Bright S, Moyers JS, Zhang C, et al. FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. J Cell Physiol (2008) 215:1-7. doi:10.1002/jcp.21357
8. Suzuki M, Uehara Y, Motomura-Matsuzaka K, Oki J, Koyama Y, Kimura M, et al. BetaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol (2008) 22:1006-14. doi:10.1210/me.2007-0313
9. Itoh N. Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease. Cell Tissue Res (2010) 342:1-11. doi:10.1007/s00441-010-1024-2
10. Long YC, Kharitonenkov A. Hormone-like fibroblast growth factors and metabolic regulation. Biochim Biophys Acta (2011) 1812:791-5. doi:10.1016/j.bbadis.2011.04.002
11. Badman MK, Koester A, Flier JS, Kharitonenkov A, Maratos-Flier E. Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology (2009) 150:4931-40. doi:10.1210/en.2009-0532
12. Planavila A, Redondo I, Hondares E, Vinciguerra M, Munts C, Iglesias R, et al. Fibroblast growth factor 21 protects against cardiac hypertrophy in mice. Nat Commun (2013) 4:2019. doi:10.1038/ncomms3019
13. Mraz M, Bartlova M, Lacinova Z, Michalsky D, Kasalicky M, Haluzikova D, et al. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (2009) 71:369-75. doi:10.1111/j.1365-2265.2008.03502.x
14. Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F, et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes (2008) 57:1246-53. doi:10.2337/db07-1476
15. Chavez AO, Molina-Carrion M, Abdul-Ghani MA, Folli F, Defronzo RA, Tripathy D. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care (2009) 32:1542-6. doi:10.2337/dc09-0684
16. Xiao Y, Xu A, Law LS, Chen C, Li H, Li X, et al. Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes. J Clin Endocrinol Metab (2012) 97:E54-8. doi:10.1210/jc.2011-1930
17. Li H, Bao Y, Xu A, Pan X, Lu J, Wu H, et al. Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects. J Clin Endocrinol Metab (2009) 94:2151-6. doi:10.1210/jc.2008-2331
18. Yilmaz Y, Eren F, Yonal O, Kurt R, Aktas B, Celikel CA, et al. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur J Clin Invest (2010) 40:887-92. doi:10.1111/j.1365-2362.2010.02338.x
19. Li H, Fang Q, Gao F, Fan J, Zhou J, Wang X, et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol (2010) 53:934-40. doi:10.1016/j.jhep.2010.05.018
20. Lin Z, Wu Z, Yin X, Liu Y, Yan X, Lin S, et al. Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS One (2010) 5:e15534. doi:10.1371/journal.pone.0015534
21. Shen Y, Ma X, Zhou J, Pan X, Hao Y, Zhou M, et al. Additive relationship between serum fibroblast growth factor 21 level and coronary artery disease. Cardiovasc Diabetol (2013) 12:124. doi:10.1186/1475-2840-12-124
22. Chow WS, Xu A, Woo YC, Tso AW, Cheung SC, Fong CH, et al. Serum fibroblast growth factor-21 levels are associated with carotid atherosclerosis independent of established cardiovascular risk factors. Arterioscler Thromb Vasc Biol (2013) 33:2454-9. doi:10.1161/ATVBAHA.113.301599
23. Hindricks J, Ebert T, Bachmann A, Kralisch S, Lossner U, Kratzsch J, et al. Serum levels of fibroblast growth factor-21 are increased in chronic and acute renal dysfunction. Clin Endocrinol (2014) 80:918-24. doi:10.1111/cen.12380
24. Lin Z, Zhou Z, Liu Y, Gong Q, Yan X, Xiao J, et al. Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese. PLoS One (2011) 6:e18398. doi:10.1371/journal.pone.0018398
25. Lee P, Brychta RJ, Linderman J, Smith S, Chen KY, Celi FS. Mild cold exposure modulates fibroblast growth factor 21 (FGF21) diurnal rhythm in humans: relationship between FGF21 levels, lipolysis, and cold-induced thermogenesis. J Clin Endocrinol Metab (2013) 98:E98-102. doi:10.1210/jc.2012-3107
26. Hanssen MJ, Broeders E, Samms RJ, Vosselman MJ, van der Lans AA, Cheng CC, et al. Serum FGF21 levels are associated with brown adipose tissue activity in humans. Sci Rep (2015) 5:10275. doi:10.1038/srep10275
27. Kliewer SA, Mangelsdorf DJ. Fibroblast growth factor 21: from pharmacology to physiology. Am J Clin Nutr (2010) 91:254S-7S. doi:10.3945/ajcn.2009.28449B
28. Kharitonenkov A, Larsen P. FGF21 reloaded: challenges of a rapidly growing field. Trends Endocrinol Metab (2011) 22:81-6. doi:10.1016/j.tem.2010.11.003
29. Potthoff MJ, Kliewer SA, Mangelsdorf DJ. Endocrine fibroblast growth factors 15/19 and 21: from feast to famine. Genes Dev (2012) 26:312-24. doi:10.1101/gad.184788.111
30. Angelin B, Larsson TE, Rudling M. Circulating fibroblast growth factors as metabolic regulators - a critical appraisal. Cell Metab (2012) 16:693-705. doi:10.1016/j.cmet.2012.11.001
31. Kharitonenkov A, Adams AC. Inventing new medicines: the FGF21 story. Mol Metab (2014) 3:221-9. doi:10.1016/j.molmet.2013.12.003
32. Zhang J, Li Y. Fibroblast growth factor 21, the endocrine FGF pathway and novel treatments for metabolic syndrome. Drug Discov Today (2014) 19:579-89. doi:10.1016/j.drudis.2013.10.021
33. Gimeno RE, Moller DE. FGF21-based pharmacotherapy - potential utility for metabolic disorders. Trends Endocrinol Metab (2014) 25:303-11. doi:10.1016/j.tem.2014.03.001
34. Owen BM, Mangelsdorf DJ, Kliewer SA. Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21. Trends Endocrinol Metab (2015) 26:22-9. doi:10.1016/j.tem.2014.10.002
35. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, et al. FGF-21 as a novel metabolic regulator. J Clin Invest (2005) 115:1627-35. doi:10.1172/JCI23606
36. Ding X, Boney-Montoya J, Owen BM, Bookout AL, Coate KC, Mangelsdorf DJ, et al. BetaKlotho is required for fibroblast growth factor 21 effects on growth and metabolism. Cell Metab (2012) 16:387-93. doi:10.1016/j.cmet.2012.08.002
37. Zhang Y, Xie Y, Berglund ED, Coate KC, He TT, Katafuchi T, et al. The starvation hormone, fibroblast growth factor-21, extends lifespan in mice. Elife (2012) 1:e00065. doi:10.7554/eLife.00065
38. Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y, et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology (2008) 149:6018-27. doi:10.1210/en.2008-0816
39. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes (2009) 58:250-9. doi:10.2337/db08-0392
40. Berglund ED, Li CY, Bina HA, Lynes SE, Michael MD, Shanafelt AB, et al. Fibroblast growth factor 21 controls glycemia via regulation of hepatic glucose flux and insulin sensitivity. Endocrinology (2009) 150:4084-93. doi:10.1210/en.2009-0221
41. Xu J, Stanislaus S, Chinookoswong N, Lau YY, Hager T, Patel J, et al. Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models - association with liver and adipose tissue effects. Am J Physiol Endocrinol Metab (2009) 297:E1105-14. doi:10.1152/ajpendo.00348.2009
42. Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno XT, et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology (2007) 148:774-81. doi:10.1210/en.2006-1168
43. Arner P, Pettersson A, Mitchell PJ, Dunbar JD, Kharitonenkov A, Ryden M. FGF21 attenuates lipolysis in human adipocytes - a possible link to improved insulin sensitivity. FEBS Lett (2008) 582:1725-30. doi:10.1016/j.febslet.2008.04.038
44. Li X, Ge H, Weiszmann J, Hecht R, Li YS, Veniant MM, et al. Inhibition of lipolysis may contribute to the acute regulation of plasma FFA and glucose by FGF21 in ob/ob mice. FEBS Lett (2009) 583:3230-4. doi:10.1016/j.febslet.2009.09.012
45. Holland WL, Adams AC, Brozinick JT, Bui HH, Miyauchi Y, Kusminski CM, et al. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metab (2013) 17:790-7. doi:10.1016/j.cmet.2013.03.019
46. Lin Z, Tian H, Lam KS, Lin S, Hoo RC, Konishi M, et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab (2013) 17:779-89. doi:10.1016/j.cmet.2013.04.005
47. Shimomura I, Hammer RE, Richardson JA, Ikemoto S, Bashmakov Y, Goldstein JL, et al. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev (1998) 12:3182-94. doi:10.1101/gad.12.20.3182
48. Veniant MM, Hale C, Helmering J, Chen MM, Stanislaus S, Busby J, et al. FGF21 promotes metabolic homeostasis via white adipose and leptin in mice. PLoS One (2012) 7:e40164. doi:10.1371/journal.pone.0040164
49. Foltz IN, Hu S, King C, Wu X, Yang C, Wang W, et al. Treating diabetes and obesity with an FGF21-mimetic antibody activating the betaKlotho/FGFR1c receptor complex. Sci Transl Med (2012) 4:162ra153. doi:10.1126/scitranslmed.3004690
50. Adams AC, Yang C, Coskun T, Cheng CC, Gimeno RE, Luo Y, et al. The breadth of FGF21's metabolic actions are governed by FGFR1 in adipose tissue. Mol Metab (2013) 2:31. doi:10.1016/j.molmet.2012.08.007
51. Kurosu H, Choi M, Ogawa Y, Dickson AS, Goetz R, Eliseenkova AV, et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem (2007) 282:26687-95. doi:10.1074/jbc.M704165200
52. Fisher FM, Estall JL, Adams AC, Antonellis PJ, Bina HA, Flier JS, et al. Integrated regulation of hepatic metabolism by fibroblast growth factor 21 (FGF21) in vivo. Endocrinology (2011) 152:2996-3004. doi:10.1210/en.2011-0281
53. Fisher FM, Kleiner S, Douris N, Fox EC, Mepani RJ, Verdeguer F, et al. FGF21 regulates PGC-1alpha and browning of white adipose tissues in adaptive thermogenesis. Genes Dev (2012) 26:271-81. doi:10.1101/gad.177857.111
54. Chartoumpekis DV, Habeos IG, Ziros PG, Psyrogiannis AI, Kyriazopoulou VE, Papavassiliou AG. Brown adipose tissue responds to cold and adrenergic stimulation by induction of FGF21. Mol Med (2011) 17:736-40. doi:10.2119/molmed.2011.00075
55. Hondares E, Iglesias R, Giralt A, Gonzalez FJ, Giralt M, Mampel T, et al. Thermogenic activation induces FGF21 expression and release in brown adipose tissue. J Biol Chem (2011) 286:12983-90. doi:10.1074/jbc.M110.215889
56. Samms RJ, Smith DP, Cheng CC, Antonellis PP, Perfield JW II, Kharitonenkov A, et al. Discrete aspects of FGF21 in vivo pharmacology do not require UCP1. Cell Rep (2015) 11:991-9. doi:10.1016/j.celrep.2015.04.046
57. Veniant MM, Sivits G, Helmering J, Komorowski R, Lee J, Fan W, et al. Pharmacologic effects of FGF21 are independent of the "browning" of white adipose tissue. Cell Metab (2015) 21:731-8. doi:10.1016/j.cmet.2015.04.019
58. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab (2007) 5:426-37. doi:10.1016/j.cmet.2007.05.002
59. Lundasen T, Hunt MC, Nilsson LM, Sanyal S, Angelin B, Alexson SE, et al. PPARalpha is a key regulator of hepatic FGF21. Biochem Biophys Res Commun (2007) 360:437-40. doi:10.1016/j.bbrc.2007.06.068
60. Liu WY, Huang S, Shi KQ, Zhao CC, Chen LL, Braddock M, et al. The role of fibroblast growth factor 21 in the pathogenesis of liver disease: a novel predictor and therapeutic target. Expert Opin Ther Targets (2014) 18:1305-13. doi:10.1517/14728222.2014.944898
61. Fisher FM, Chui PC, Nasser IA, Popov Y, Cunniff JC, Lundasen T, et al. Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets. Gastroenterology (2014) 147:1073-83.e6. doi:10.1053/j.gastro.2014.07.044
62. Jian WX, Peng WH, Jin J, Chen XR, Fang WJ, Wang WX, et al. Association between serum fibroblast growth factor 21 and diabetic nephropathy. Metabolism (2012) 61:853-9. doi:10.1016/j.metabol.2011.10.012
63. Kim HW, Lee JE, Cha JJ, Hyun YY, Kim JE, Lee MH, et al. Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db/db mice. Endocrinology (2013) 154:3366-76. doi:10.1210/en.2012-2276
64. Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS, et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes (2010) 59:2781-9. doi:10.2337/db10-0193
65. An SY, Lee MS, Yi SA, Ha ES, Han SJ, Kim HJ, et al. Serum fibroblast growth factor 21 was elevated in subjects with type 2 diabetes mellitus and was associated with the presence of carotid artery plaques. Diabetes Res Clin Pract (2012) 96:196-203. doi:10.1016/j.diabres.2012.01.004
66. Xiao Y, Liu L, Xu A, Zhou P, Long Z, Tu Y, et al. Serum fibroblast growth factor 21 levels are related to subclinical atherosclerosis in patients with type 2 diabetes. Cardiovasc Diabetol (2015) 14:72. doi:10.1186/s12933-015-0229-9
67. Planavila A, Redondo-Angulo I, Ribas F, Garrabou G, Casademont J, Giralt M, et al. Fibroblast growth factor 21 protects the heart from oxidative stress. Cardiovasc Res (2015) 106:19-31. doi:10.1093/cvr/cvu263
68. Brahma MK, Adam RC, Pollak NM, Jaeger D, Zierler KA, Pocher N, et al. Fibroblast growth factor 21 is induced upon cardiac stress and alters cardiac lipid homeostasis. J Lipid Res (2014) 55:2229-41. doi:10.1194/jlr.M044784
69. So WY, Cheng Q, Chen L, Evans-Molina C, Xu A, Lam KS, et al. High glucose represses beta-klotho expression and impairs fibroblast growth factor 21 action in mouse pancreatic islets: involvement of peroxisome proliferator-activated receptor gamma signaling. Diabetes (2013) 62:3751-9. doi:10.2337/db13-0645
70. Gaich G, Chien JY, Fu H, Glass LC, Deeg MA, Holland WL, et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab (2013) 18:333-40. doi:10.1016/j.cmet.2013.08.005
71. Adams AC, Halstead CA, Hansen BC, Irizarry AR, Martin JA, Myers SR, et al. LY2405319, an engineered FGF21 variant, improves the metabolic status of diabetic monkeys. PLoS One (2013) 8:e65763. doi:10.1371/journal.pone.0065763
72. Ye XL, Gao HS, Wang WF, Ren GP, Liu MY, He K, et al. [Optimization and characterization of a novel FGF21 mutant]. Yao Xue Xue Bao (2012) 47:897-903.
73. Wu X, Lemon B, Li X, Gupte J, Weiszmann J, Stevens J, et al. C-terminal tail of FGF19 determines its specificity toward klotho co-receptors. J Biol Chem (2008) 283:33304-9. doi:10.1074/jbc.M803319200
74. Yie J, Hecht R, Patel J, Stevens J, Wang W, Hawkins N, et al. FGF21 N-and C-termini play different roles in receptor interaction and activation. FEBS Lett (2009) 583:19-24. doi:10.1016/j.febslet.2008.11.023
75. Micanovic R, Raches DW, Dunbar JD, Driver DA, Bina HA, Dickinson CD, et al. Different roles of N-and C-termini in the functional activity of FGF21. J Cell Physiol (2009) 219:227-34. doi:10.1002/jcp.21675
76. Hecht R, Li YS, Sun J, Belouski E, Hall M, Hager T, et al. Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of type 2 diabetes. PLoS One (2012) 7:e49345. doi:10.1371/journal.pone.0049345
77. Goetz R, Ohnishi M, Ding X, Kurosu H, Wang L, Akiyoshi J, et al. Klotho coreceptors inhibit signaling by paracrine fibroblast growth factor 8 subfamily ligands. Mol Cell Biol (2012) 32:1944-54. doi:10.1128/MCB.06603-11
78. Smith R, Duguay A, Weiszmann J, Stanislaus S, Belouski E, Cai L, et al. A novel approach to improve the function of FGF21. BioDrugs (2013) 27:159-66. doi:10.1007/s40259-013-0013-x
79. Huang Z, Wang H, Lu M, Sun C, Wu X, Tan Y, et al. A better anti-diabetic recombinant human fibroblast growth factor 21 (rhFGF21) modified with polyethylene glycol. PLoS One (2011) 6:e20669. doi:10.1371/journal.pone.0020669
80. Xu J, Bussiere J, Yie J, Sickmier A, An P, Belouski E, et al. Polyethylene glycol modified FGF21 engineered to maximize potency and minimize vacuole formation. Bioconjug Chem (2013) 24:915-25. doi:10.1021/bc300603k
81. Mu J, Pinkstaff J, Li Z, Skidmore L, Li N, Myler H, et al. FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents. Diabetes (2012) 61:505-12. doi:10.2337/db11-0838
82. Hager T, Spahr C, Xu J, Salimi-Moosavi H, Hall M. Differential enzyme-linked immunosorbent assay and ligand-binding mass spectrometry for analysis of biotransformation of protein therapeutics: application to various FGF21 modalities. Anal Chem (2013) 85:2731-8. doi:10.1021/ac303203y
83. Veniant MM, Komorowski R, Chen P, Stanislaus S, Winters K, Hager T, et al. Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys. Endocrinology (2012) 153:4192-203. doi:10.1210/en.2012-1211
84. Huang J, Ishino T, Chen G, Rolzin P, Osothprarop TF, Retting K, et al. Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody. J Pharmacol Exp Ther (2013) 346:270-80. doi:10.1124/jpet.113.204420
85. Suh JM, Jonker JW, Ahmadian M, Goetz R, Lackey D, Osborn O, et al. Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer. Nature (2014) 513:436-9. doi:10.1038/nature13540
86. Wu X, Li Y. Understanding the structure-function relationship between FGF19 and its mitogenic and metabolic activities. Adv Exp Med Biol (2012) 728:195-213. doi:10.1007/978-1-4614-0887-1_13
87. Wu X, Ge H, Lemon B, Vonderfecht S, Weiszmann J, Hecht R, et al. FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation. J Biol Chem (2010) 285:5165-70. doi:10.1074/jbc.M109.068783
88. Wu AL, Coulter S, Liddle C, Wong A, Eastham-Anderson J, French DM, et al. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. PLoS One (2011) 6:e17868. doi:10.1371/journal.pone.0017868
89. French DM, Lin BC, Wang M, Adams C, Shek T, Hotzel K, et al. Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. PLoS One (2012) 7:e36713. doi:10.1371/journal.pone.0036713
90. Wu X, Ge H, Lemon B, Vonderfecht S, Baribault H, Weiszmann J, et al. Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19). Proc Natl Acad Sci U S A (2010) 107:14158-63. doi:10.1073/pnas.1009427107
91. Ge H, Baribault H, Vonderfecht S, Lemon B, Weiszmann J, Gardner J, et al. Characterization of a FGF19 variant with altered receptor specificity revealed a central role for FGFR1c in the regulation of glucose metabolism. PLoS One (2012) 7:e33603. doi:10.1371/journal.pone.0033603
92. Luo J, Ko B, Elliott M, Zhou M, Lindhout DA, Phung V, et al. A nontumorigenic variant of FGF19 treats cholestatic liver diseases. Sci Transl Med (2014) 6:247ra100. doi:10.1126/scitranslmed.3009098
93. Jonker JW, Suh JM, Atkins AR, Ahmadian M, Li P, Whyte J, et al. A PPARgamma-FGF1 axis is required for adaptive adipose remodelling and metabolic homeostasis. Nature (2012) 485:391-4. doi:10.1038/nature10998
94. Wu X, Weiszmann J, Ge H, Baribault H, Stevens J, Hawkins N, et al. A unique FGF23 with the ability to activate FGFR signaling through both alphaKlotho and betaKlotho. J Mol Biol (2012) 418:82-9. doi:10.1016/j.jmb.2012.02.027
95. Goetz R, Ohnishi M, Kir S, Kurosu H, Wang L, Pastor J, et al. Conversion of a paracrine fibroblast growth factor into an endocrine fibroblast growth factor. J Biol Chem (2012) 287:29134-46. doi:10.1074/jbc.M112.342980
96. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature (2006) 444:770-4. doi:10.1038/nature05315
97. Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem (2006) 281:6120-3. doi:10.1074/jbc.C500457200
98. Wu AL, Kolumam G, Stawicki S, Chen Y, Li J, Zavala-Solorio J, et al. Amelioration of type 2 diabetes by antibody-mediated activation of fibroblast growth factor receptor 1. Sci Transl Med (2011) 3:113ra126. doi:10.1126/scitranslmed.3002669
99. Lelliott CJ, Ahnmark A, Admyre T, Ahlstedt I, Irving L, Keyes F, et al. Monoclonal antibody targeting of fibroblast growth factor receptor 1c ameliorates obesity and glucose intolerance via central mechanisms. PLoS One (2014) 9:e112109. doi:10.1371/journal.pone.0112109
100. Wu AL, Feng B, Chen MZ, Kolumam G, Zavala-Solorio J, Wyatt SK, et al. Antibody-mediated activation of FGFR1 induces FGF23 production and hypophosphatemia. PLoS One (2013) 8:e57322. doi:10.1371/journal.pone.0057322
101. Smith R, Duguay A, Bakker A, Li P, Weiszmann J, Thomas MR, et al. FGF21 can be mimicked in vitro and in vivo by a novel anti-FGFR1c/beta-klotho bispecific protein. PLoS One (2013) 8:e61432. doi:10.1371/journal.pone.0061432
102. Kolumam G, Chen MZ, Tong R, Zavala-Solorio J, Kates L, van Bruggen N, et al. Sustained brown fat stimulation and insulin sensitization by a humanized bispecific antibody agonist for fibroblast growth factor receptor 1/βKlotho complex. EBioMedicine (2015) 2:730-43. doi:10.1016/j.ebiom.2015.05.028
103. Inagaki T, Lin VY, Goetz R, Mohammadi M, Mangelsdorf DJ, Kliewer SA. Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metab (2008) 8:77-83. doi:10.1016/j.cmet.2008.05.006
104. Wu S, Levenson A, Kharitonenkov A, De Luca F. Fibroblast growth factor 21 (FGF21) inhibits chondrocyte function and growth hormone action directly at the growth plate. J Biol Chem (2012) 287:26060-7. doi:10.1074/jbc.M112.343707
105. Wei W, Dutchak PA, Wang X, Ding X, Wang X, Bookout AL, et al. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor gamma. Proc Natl Acad Sci U S A (2012) 109:3143-8. doi:10.1073/pnas.1200797109
106. Bookout AL, de Groot MH, Owen BM, Lee S, Gautron L, Lawrence HL, et al. FGF21 regulates metabolism and circadian behavior by acting on the nervous system. Nat Med (2013) 19:1147-52. doi:10.1038/nm.3249
107. Dutchak PA, Katafuchi T, Bookout AL, Choi JH, Yu RT, Mangelsdorf DJ, et al. Fibroblast growth factor-21 regulates PPARgamma activity and the antidiabetic actions of thiazolidinediones. Cell (2012) 148:556-67. doi:10.1016/j.cell.2011.11.062
108. Owen BM, Bookout AL, Ding X, Lin VY, Atkin SD, Gautron L, et al. FGF21 contributes to neuroendocrine control of female reproduction. Nat Med (2013) 19:1153-6. doi:10.1038/nm.3250
109. Camacho RC, Zafian PT, Achanfuo-Yeboah J, Manibusan A, Berger JP. Pegylated Fgf21 rapidly normalizes insulin-stimulated glucose utilization in diet-induced insulin resistant mice. Eur J Pharmacol (2013) 715:41-5. doi:10.1016/j.ejphar.2013.06.023